Avenue Therapeutics, Inc. (ATXI) EPS Estimated At $-0.39

October 11, 2018 - By Peter Kolinski

Analysts expect Avenue Therapeutics, Inc. (NASDAQ:ATXI) to report $-0.39 EPS on November, 8.They anticipate $0.09 EPS change or 30.00 % from last quarter’s $-0.3 EPS. After having $-0.45 EPS previously, Avenue Therapeutics, Inc.’s analysts see -13.33 % EPS growth. The stock increased 91.43% or $1.92 during the last trading session, reaching $4.02. About 538,501 shares traded or 3151.82% up from the average. Avenue Therapeutics, Inc. (NASDAQ:ATXI) has declined 45.48% since October 11, 2017 and is downtrending. It has underperformed by 61.10% the S&P500.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes an intravenous formulation of tramadol HCI principally for use in the acute/intensive care hospital setting. The company has market cap of $42.43 million. The Company’s product candidate is IV Tramadol for the treatment of post-operative pain. It currently has negative earnings. The firm was founded in 2015 and is based in New York, New York.

More important recent Avenue Therapeutics, Inc. (NASDAQ:ATXI) news were published by: Benzinga.com which released: “38 Stocks Moving In Tuesday’s Mid-Day Session” on October 02, 2018, also Benzinga.com published article titled: “34 Stocks Moving In Thursday’s Mid-Day Session”, Benzinga.com published: “The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares” on September 18, 2018. More interesting news about Avenue Therapeutics, Inc. (NASDAQ:ATXI) was released by: Benzinga.com and their article: “The Daily Biotech Pulse: Affimed’s Cancer Drug Placed On Clinical Hold, Celgene’s Positive Scalp Psoriasis Trial” with publication date: October 09, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>